Alembic Limited (ALEMBICLTD) fundamentals

Alembic Limited is a listed company in Realty, part of the Realty sector, listed on the NSE as ALEMBICLTD (ISIN INE426A01027). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.

What Alembic Limited does

Alembic Limited is an India-based company engaged in the business of development, manufacturing, and marketing of pharmaceutical products. The Company's segments include the Active Pharmaceutical Ingredients Business and the Real Estate Business. The Active Pharmaceutical Ingredients Business is engaged in the manufacturing and marketing of fermentation and chemistry-based active pharmaceutical ingredients (API). The Real Estate Business is engaged in the construction of residential and commercial real estate projects and project management and marketing consultancy. The Company provides certain commercial properties on a lease basis to various tenants. The Company is also engaged in research and development activities in Vadodara. It is also engaged in power generation through co-generation.

Valuation and market data

Last close₹105.30
Market capitalisation₹1,073 crore
Enterprise value₹1,115 crore
P/E (TTM)8.52
Price to book0.44
Price to sales (TTM)2.18
Book value per share₹239.99
Dividend yield227.92%
SectorRealty
IndustryRealty
Listed sinceWed Sep 22

Annual results

PeriodRevenueProfit before taxNet profitEPS
Mar 2026₹305 crore₹147 crore₹125 crore4.85
Mar 2025₹289 crore₹152 crore₹142 crore5.53
Mar 2024₹207 crore₹103 crore₹93 crore3.62
Mar 2023₹187 crore₹85 crore₹79 crore3.09

Figures are as reported (standalone), in ₹ crore.

Shareholding pattern

As of Jun 2026:

Promoters70.9%
Foreign institutions (FII)1.3%
Mutual funds0.0%
Other domestic institutions0.1%
Retail and others27.8%

More on BreakPoint

FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.

Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.